Patents by Inventor Emma Andersson

Emma Andersson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYSTEINE PROTEASE
    Publication number: 20240360432
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG and in vitro generation of F(ab?)2 fragments.
    Type: Application
    Filed: May 18, 2021
    Publication date: October 31, 2024
    Inventors: Emma Andersson Nordahl, Christian Kjellman, Kaisa Karhumaa, Karl Markus Roupé, Robert Bockermann, Sofia Järnum
  • CYSTEINE PROTEASE
    Publication number: 20230357741
    Abstract: The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.
    Type: Application
    Filed: May 16, 2023
    Publication date: November 9, 2023
    Inventors: Christian Kjellman, Sofia Jarnum, Emma Andersson Nordahl
  • Antiviral compounds
    Patent number: 8993622
    Abstract: The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 31, 2015
    Assignee: Eirium AB
    Inventors: Göran Wadell, Karin Edlund, Marten Strand, Emma Andersson, Christopher Öberg, Mikael Elofsson, Ya-Fang Mei
  • Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases
    Patent number: 8835439
    Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: September 16, 2014
    Assignee: Proximagen Limited
    Inventors: Tom Fleck, Magnus Cernerud, Helena Lundstrom, Claes Lofstrom, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
  • ANTIVIRAL COMPOUNDS
    Publication number: 20130210915
    Abstract: The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.
    Type: Application
    Filed: June 13, 2011
    Publication date: August 15, 2013
    Inventors: Göran Wadell, Karin Edlund, Marten Strand, Emma Andersson, Christopher Öberg, Mikael Elofsson, Ya-Fang Mei
  • (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof
    Patent number: 8410113
    Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: April 2, 2013
    Assignee: Biovitrum AB (publ)
    Inventors: Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren, Bruce Fleck
  • (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF
    Publication number: 20120010410
    Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 12, 2012
    Inventors: Tom Fleck, Bruce Fleck, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
  • SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE
    Publication number: 20120004241
    Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.
    Type: Application
    Filed: September 16, 2011
    Publication date: January 5, 2012
    Inventors: Tom Fleck, Bruce Fleck, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
  • Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine
    Patent number: 8030316
    Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: October 4, 2011
    Assignee: Biovitrum AB (Publ)
    Inventors: Tom Fleck, Bruce Fleck, legal representative, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
  • Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine
    Patent number: 7820677
    Abstract: Stable acid addition salts of certain 2,3-disubstituted pyrazine compounds that are selective for the 5-HT2c receptor and therapeutically active in the central nervous system are described.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: October 26, 2010
    Inventors: Tom Fleck, Bruce Fleck, legal representative, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
  • NOVEL PROCESS
    Publication number: 20100256374
    Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.
    Type: Application
    Filed: June 17, 2010
    Publication date: October 7, 2010
    Inventors: Tom Fleck, Bruce Fleck, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
  • Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds
    Patent number: 7129354
    Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1–R4 are each independently selected from the group consisting of hydrogen, halogen, C1–C6-alkyl, C1–C6-alkoxy, and di-C1–C6-alkylamino-C2–C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: October 31, 2006
    Assignee: Biovitrum AB
    Inventors: Bruce Fleck, legal representative, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren, Tom Fleck, deceased
  • Novel process
    Publication number: 20060142578
    Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. (I)n one aspect, the invention relates to a process for the preparation of compounds of the general formula ((I)): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.
    Type: Application
    Filed: February 22, 2006
    Publication date: June 29, 2006
    Inventors: Tom Fleck, Bruce Fleck, Magnus Cernerud, Helena Lundstrom, Claes Lofstrom, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren